TFPI2 and colorectal carcinoma: Three biomarker panels including methylated SCDC2 alongside methylated TFPI2 achieved remarkable performances in terms of their overall CRC sensitivities and specificities which ranged from 90.0 to 94.9% and 94.0–98.1% respectively.